Kyverna Therapeutics (KYTX) Corporate presentation summary

Strategic vision and market opportunity

• Aims to pioneer CAR T therapy for autoimmune diseases, focusing on neuroimmunology indications like SPS, gMG, and PMS.

• Positioned as a first-mover in SPS with a best-in-class profile and potential for premium pricing.

• Significant commercial opportunity with ~6,000 SPS and ~80,000 gMG diagnosed patients in the U.S.

• Focused launch strategy targets ~10 high-value SPS centers for rapid adoption.

• Dual-source U.S. manufacturing supports scalable growth and biologics-like margins.

Clinical data and efficacy

• Miv-cel demonstrated durable, drug-free, disease-free remission with a single dose in SPS and gMG.

• In SPS, 81% of patients achieved ≥20% improvement in T25FW at 16 weeks; 67% of those needing walking aids no longer required them.

• In gMG, 100% of patients had clinically meaningful responses in MG-ADL and QMG scores, with 57% reaching minimal symptom expression.

• PMS studies showed improved or stable EDSS and all patients remained off other immunotherapies.

• Natural history study contextualizes transformative outcomes versus standard care in SPS.

Safety and tolerability

• No high-grade CRS or ICANS observed in SPS or gMG trials; adverse events were manageable and resolved.

• In SPS, 92% experienced low-grade CRS, 12% had ICANS, and 15% had grade 3/4 neutropenia.

• In gMG, all CRS events were low-grade and manageable; no ICANS observed.

• Safety profile supports potential for outpatient administration.